The development of the clinical pathway for a moderate to severe psoriasis in Malaysia

Aniza Ismail, Nor Azmaniza Azizam, Saperi Sulong, Norazirah Md Nor, Zafar Ahmed, Azura Mohd Affandi, Chan Lee Chin, Gurcharan Jit Singh, Kho Wee Meng, Tan Wooi Chiang, Wan Noor Hasbee Wan Abdullah

Research output: Contribution to journalArticle

Abstract

Introduction: Clinical Pathway (CP) is a care plan provided for patients with medical problems using organized procedures. The establishment of standardization, the reduction in terms of the differences between each treatment process, cost containment, and the improvement of treatment quality are essential. Therefore, CP has been utilized in healthcare settings for these purposes. However, as the criteria for the formulation of CP is unspecified, there has been lack of agreement regarding the effectiveness of CP among researchers and clinicians. Based on general knowledge, there was no evidence about the use of CP for a moderate to severe Psoriasis. Objective: This paper describes the collaborative efforts between UKMMC and MOH hospitals in developing a CP for moderate to severe psoriasis in Malaysia. Methodology: The development of the CP consisted of three steps, where: 1) composition of team, 2) standardization of case definition, 3) development of the draft for CP, 4) modification of CP requirement for agreement, and 5) finalization of CP. Following that, an agreement was achieved amongst all dermatologists regarding the specifications for moderate to severe psoriasis, which were BSA < 10, PASI < 10, DLQI < 10. Result: the sections of final CP consisted of; a) general examination where weight, height, BSA, PASI, DLQI, laboratory investigation, and procedural examination were involved, b) the sections for modality's requirements, where the list of drugs specialized for four modalities were involved; they were topical, phototherapy systemic and biologic, and c) additional plans for treatment, where referral to other specialists, counseling, and follow up were involved. Conclusion: This CP was developed in compliance with Evidence Based Medicine. However, future research is required in order to address the use of CP under certain conditions with standardized criteria, for the acquirement of homogenous and comparable results.

Original languageEnglish
Pages (from-to)173-176
Number of pages4
JournalInternational Medical Journal
Volume25
Issue number3
Publication statusPublished - 1 Jun 2018
Externally publishedYes

Fingerprint

Critical Pathways
Malaysia
Psoriasis
Phototherapy
Cost Control
Evidence-Based Medicine
Quality Improvement
Health Care Costs
Counseling
Referral and Consultation

Keywords

  • Clinical pathway
  • Psoriasis

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Ismail, A., Azizam, N. A., Sulong, S., Md Nor, N., Ahmed, Z., Mohd Affandi, A., ... Wan Abdullah, W. N. H. (2018). The development of the clinical pathway for a moderate to severe psoriasis in Malaysia. International Medical Journal, 25(3), 173-176.

The development of the clinical pathway for a moderate to severe psoriasis in Malaysia. / Ismail, Aniza; Azizam, Nor Azmaniza; Sulong, Saperi; Md Nor, Norazirah; Ahmed, Zafar; Mohd Affandi, Azura; Chin, Chan Lee; Singh, Gurcharan Jit; Meng, Kho Wee; Chiang, Tan Wooi; Wan Abdullah, Wan Noor Hasbee.

In: International Medical Journal, Vol. 25, No. 3, 01.06.2018, p. 173-176.

Research output: Contribution to journalArticle

Ismail, A, Azizam, NA, Sulong, S, Md Nor, N, Ahmed, Z, Mohd Affandi, A, Chin, CL, Singh, GJ, Meng, KW, Chiang, TW & Wan Abdullah, WNH 2018, 'The development of the clinical pathway for a moderate to severe psoriasis in Malaysia', International Medical Journal, vol. 25, no. 3, pp. 173-176.
Ismail, Aniza ; Azizam, Nor Azmaniza ; Sulong, Saperi ; Md Nor, Norazirah ; Ahmed, Zafar ; Mohd Affandi, Azura ; Chin, Chan Lee ; Singh, Gurcharan Jit ; Meng, Kho Wee ; Chiang, Tan Wooi ; Wan Abdullah, Wan Noor Hasbee. / The development of the clinical pathway for a moderate to severe psoriasis in Malaysia. In: International Medical Journal. 2018 ; Vol. 25, No. 3. pp. 173-176.
@article{40d769da22354b45af761ba6fd6c21f9,
title = "The development of the clinical pathway for a moderate to severe psoriasis in Malaysia",
abstract = "Introduction: Clinical Pathway (CP) is a care plan provided for patients with medical problems using organized procedures. The establishment of standardization, the reduction in terms of the differences between each treatment process, cost containment, and the improvement of treatment quality are essential. Therefore, CP has been utilized in healthcare settings for these purposes. However, as the criteria for the formulation of CP is unspecified, there has been lack of agreement regarding the effectiveness of CP among researchers and clinicians. Based on general knowledge, there was no evidence about the use of CP for a moderate to severe Psoriasis. Objective: This paper describes the collaborative efforts between UKMMC and MOH hospitals in developing a CP for moderate to severe psoriasis in Malaysia. Methodology: The development of the CP consisted of three steps, where: 1) composition of team, 2) standardization of case definition, 3) development of the draft for CP, 4) modification of CP requirement for agreement, and 5) finalization of CP. Following that, an agreement was achieved amongst all dermatologists regarding the specifications for moderate to severe psoriasis, which were BSA < 10, PASI < 10, DLQI < 10. Result: the sections of final CP consisted of; a) general examination where weight, height, BSA, PASI, DLQI, laboratory investigation, and procedural examination were involved, b) the sections for modality's requirements, where the list of drugs specialized for four modalities were involved; they were topical, phototherapy systemic and biologic, and c) additional plans for treatment, where referral to other specialists, counseling, and follow up were involved. Conclusion: This CP was developed in compliance with Evidence Based Medicine. However, future research is required in order to address the use of CP under certain conditions with standardized criteria, for the acquirement of homogenous and comparable results.",
keywords = "Clinical pathway, Psoriasis",
author = "Aniza Ismail and Azizam, {Nor Azmaniza} and Saperi Sulong and {Md Nor}, Norazirah and Zafar Ahmed and {Mohd Affandi}, Azura and Chin, {Chan Lee} and Singh, {Gurcharan Jit} and Meng, {Kho Wee} and Chiang, {Tan Wooi} and {Wan Abdullah}, {Wan Noor Hasbee}",
year = "2018",
month = "6",
day = "1",
language = "English",
volume = "25",
pages = "173--176",
journal = "International Medical Journal",
issn = "1341-2051",
publisher = "Japan International Cultural Exchange Foundation",
number = "3",

}

TY - JOUR

T1 - The development of the clinical pathway for a moderate to severe psoriasis in Malaysia

AU - Ismail, Aniza

AU - Azizam, Nor Azmaniza

AU - Sulong, Saperi

AU - Md Nor, Norazirah

AU - Ahmed, Zafar

AU - Mohd Affandi, Azura

AU - Chin, Chan Lee

AU - Singh, Gurcharan Jit

AU - Meng, Kho Wee

AU - Chiang, Tan Wooi

AU - Wan Abdullah, Wan Noor Hasbee

PY - 2018/6/1

Y1 - 2018/6/1

N2 - Introduction: Clinical Pathway (CP) is a care plan provided for patients with medical problems using organized procedures. The establishment of standardization, the reduction in terms of the differences between each treatment process, cost containment, and the improvement of treatment quality are essential. Therefore, CP has been utilized in healthcare settings for these purposes. However, as the criteria for the formulation of CP is unspecified, there has been lack of agreement regarding the effectiveness of CP among researchers and clinicians. Based on general knowledge, there was no evidence about the use of CP for a moderate to severe Psoriasis. Objective: This paper describes the collaborative efforts between UKMMC and MOH hospitals in developing a CP for moderate to severe psoriasis in Malaysia. Methodology: The development of the CP consisted of three steps, where: 1) composition of team, 2) standardization of case definition, 3) development of the draft for CP, 4) modification of CP requirement for agreement, and 5) finalization of CP. Following that, an agreement was achieved amongst all dermatologists regarding the specifications for moderate to severe psoriasis, which were BSA < 10, PASI < 10, DLQI < 10. Result: the sections of final CP consisted of; a) general examination where weight, height, BSA, PASI, DLQI, laboratory investigation, and procedural examination were involved, b) the sections for modality's requirements, where the list of drugs specialized for four modalities were involved; they were topical, phototherapy systemic and biologic, and c) additional plans for treatment, where referral to other specialists, counseling, and follow up were involved. Conclusion: This CP was developed in compliance with Evidence Based Medicine. However, future research is required in order to address the use of CP under certain conditions with standardized criteria, for the acquirement of homogenous and comparable results.

AB - Introduction: Clinical Pathway (CP) is a care plan provided for patients with medical problems using organized procedures. The establishment of standardization, the reduction in terms of the differences between each treatment process, cost containment, and the improvement of treatment quality are essential. Therefore, CP has been utilized in healthcare settings for these purposes. However, as the criteria for the formulation of CP is unspecified, there has been lack of agreement regarding the effectiveness of CP among researchers and clinicians. Based on general knowledge, there was no evidence about the use of CP for a moderate to severe Psoriasis. Objective: This paper describes the collaborative efforts between UKMMC and MOH hospitals in developing a CP for moderate to severe psoriasis in Malaysia. Methodology: The development of the CP consisted of three steps, where: 1) composition of team, 2) standardization of case definition, 3) development of the draft for CP, 4) modification of CP requirement for agreement, and 5) finalization of CP. Following that, an agreement was achieved amongst all dermatologists regarding the specifications for moderate to severe psoriasis, which were BSA < 10, PASI < 10, DLQI < 10. Result: the sections of final CP consisted of; a) general examination where weight, height, BSA, PASI, DLQI, laboratory investigation, and procedural examination were involved, b) the sections for modality's requirements, where the list of drugs specialized for four modalities were involved; they were topical, phototherapy systemic and biologic, and c) additional plans for treatment, where referral to other specialists, counseling, and follow up were involved. Conclusion: This CP was developed in compliance with Evidence Based Medicine. However, future research is required in order to address the use of CP under certain conditions with standardized criteria, for the acquirement of homogenous and comparable results.

KW - Clinical pathway

KW - Psoriasis

UR - http://www.scopus.com/inward/record.url?scp=85047847441&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85047847441&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:85047847441

VL - 25

SP - 173

EP - 176

JO - International Medical Journal

JF - International Medical Journal

SN - 1341-2051

IS - 3

ER -